We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Gonadotropin--Releasing Hormone Antagonists in Prostate Cancer.
- Authors
Kittai, Adam S.; Blank, Jessica; Graff, Julie N.
- Abstract
Androgen deprivation therapy (ADT) comes in several forms, such as surgical castration or medical castration using gonadotropin-releasing hormone (GnRH) agonist or GnRH antagonist therapy. ADT is a critical treatment for high-risk and metastatic prostate cancer. There are important differences between GnRH agonists and antagonists. Here we review the mechanism of action between GnRH agonists and antagonists and the studies that led to the approval of degarelix. We also comment on the potential risks and benefits of degarelix, particularly when it comes to cardiovascular health. Finally, we describe an oral GnRH antagonist, which is not currently used in prostate cancer, but is included for completeness.
- Publication
Oncology (08909091), 2018, Vol 32, Issue 12, p599
- ISSN
0890-9091
- Publication type
Academic Journal